98%
921
2 minutes
20
Background: Cerebrospinal fluid (CSF) leaks result from dural tears due to traumatic and non-traumatic causes, potentially leading to meningitis, intracranial infections, subdural hematomas, and even death. Neuroimaging is still the standard diagnostic tool but presents economic and logistical challenges. Non-invasive biochemical methods offer valuable first-line diagnostics. This systematic review and meta-analysis evaluate the accuracy of CSF biomarkers in detecting leaks.
Objective: To assess the diagnostic accuracy of CSF biomarkers in suspected CSF leak cases.
Methods: A comprehensive search was conducted across electronic databases and citation mining from the date of inception till February 2025. The study, registered on PROSPERO (CRD42024601252), followed PRISMA 2020 guidelines. Of 455 retrieved studies, eighteen met inclusion criteria; seventeen were used for meta-analysis, involving 1,914 patients.
Results: Pooled CSF leak prevalence was 31 %. Pooled sensitivity and specificity were 0.96 (95 % CI: 0.869-0.988) and 0.946 (0.746-0.991) for Beta-2-transferrin (B2T), and 0.949 (0.909-0.972) and 0.999 (0.945-1) for Beta-trace protein (BTP). Diagnostic odds ratios (DOR) were 418.09 (48.582-3597.985) for B2T and 14,566.52 (387.368-547,756.3) for BTP.
Conclusion: CSF biomarkers show high diagnostic accuracy, offering a promising alternative to neuroimaging. Standardizing biomarker thresholds and assay methodologies are crucial for reliability. Further research should address confounding factors and variability to enhance diagnostic effectiveness. Prospero registration: The above systematic review has been registered in PROSPERO Registration Id: CRD42024601252.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cca.2025.120458 | DOI Listing |
Alzheimers Dement
September 2025
Research Service, VA San Diego Healthcare System, San Diego, California, USA.
Introduction: Among individuals who are amyloid biomarker-positive or apolipoprotein E (APOE) ε4 carriers, arterial stiffness reflected by higher pulse wave velocity (PWV) has been associated with lower cognition cross-sectionally. Less is known about longitudinal associations.
Methods: The sample included 152 older adults without dementia.
Mol Psychiatry
September 2025
Memory Center, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
Blood-based biomarkers (BBMs) have emerged as promising tools to enhance Alzheimer's disease (AD) diagnosis. Despite two-thirds of dementia cases occurring in the Global South, research on BBMs has predominantly focused on populations from the Global North. This geographical disparity hinders our understanding of BBM performance in diverse populations.
View Article and Find Full Text PDFNeurology
October 2025
Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic de Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain.
Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Hygiene, Kawasaki Medical School, Kurashiki, Japan.
T-cell therapies have proven to be a promising treatment option for cancer patients in recent years, especially in the case of chimeric antigen receptor (CAR)-T cell therapy. However, the therapy is associated with insufficient activation of T cells or poor persistence in the patient's body, which leads to incomplete elimination of cancer cells, recurrence, and genotoxicity. By extracting the splice element of PD-1 pre-mRNA using biology based on CRISPR/dCas13 in this study, our ultimate goal is to overcome the above-mentioned challenges in the future.
View Article and Find Full Text PDFACS Sens
September 2025
Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, China.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by cognitive decline and behavioral impairments, typically manifesting in the elderly and presenile population. With the rapid global aging trend, early diagnosis and treatment of AD have become increasingly urgent research priorities. The primary pathological features of AD include excessive accumulation of β-amyloid (Aβ) plaques, the formation of neurofibrillary tangles, and neuronal loss.
View Article and Find Full Text PDF